Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 7/2004

01-07-2004 | Short Communication

Catastrophic heparin-induced thrombocytopenia/thrombosis syndrome related to the use of a Port-A-Cath in a breast cancer patient receiving chemotherapy

Authors: Ming-Shen Dai, An-Tie Hsieh, Tsu-Yi Chao

Published in: Supportive Care in Cancer | Issue 7/2004

Login to get access

Abstract

Heparin-induced thrombocytopenia and thrombosis (HIT/T) syndrome is usually triggered by an immune response after repeated administration of heparin. The syndrome is strongly associated with limb deep vein thrombosis and is potentially life-threatening if unrecognized. We describe the case of a patient with compartment syndrome of the left forearm complicated by HIT/T that developed after Port-A-Cath implantation through the left subclavian vein. Prompt recognition of HIT/T, immediate withdrawal of heparin, and timely institution of thrombolytic therapy successfully prevented limb loss.
Literature
1.
Warkentin TE (2003) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535–555CrossRefPubMed
2.
Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B (1990) Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 336:1077–1078CrossRef
3.
Aird WC, Mark EJ (2002) A 53-year-old man with a myocardial infarct and thromboses after coronary-artery bypass grafting. N Engl J Med 346:1562–1570CrossRefPubMed
4.
Hong AP, Cook DJ, Sigoulin CS, Warkentin TE (2003) Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101:3049–3051CrossRefPubMed
5.
Baglin TP (2001) Heparin induced thrombocytopenia thrombosis syndrome: diagnosis and treatment. J Clin Pathol 54:272–274CrossRefPubMed
6.
Lam F, Hussain S, Li P (2001) Limb loss following the use of heparin: a lesson to be remembered. J Bone Joint Surg 83:588–589CrossRef
7.
Warkentin TE, Kelton JG (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286–1292
8.
9.
Warkentin TE (1998) Limitation of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 35 [4 Suppl 5]:17–25
10.
Mehta DP, Yoder EL, Appel J, Bergsman KL (1991) Heparin-induced thrombocytopenia and thrombosis: reversal with streptokinase: a case report and review of literature. Am J Hematol 36:275–279PubMed
11.
Murphy KD, McCrohan G, DeMarta DA, Shirodkar NB, Kwon OJ, Chopra PS (1996) The heparin-induced thrombocytopenia and thrombosis syndrome: treatment with intraarterial urokinase and systemic platelet aggregation inhibitors. Cardiovasc Intervent Radiol 19:123–127CrossRefPubMed
12.
Poullin P, Pietri PA, Lefevre P (1998) Heparin-induced thrombocytopenia with thrombosis: successful treatment with plasma exchange. Br J Haematol 102:630–631CrossRefPubMed
Metadata
Title
Catastrophic heparin-induced thrombocytopenia/thrombosis syndrome related to the use of a Port-A-Cath in a breast cancer patient receiving chemotherapy
Authors
Ming-Shen Dai
An-Tie Hsieh
Tsu-Yi Chao
Publication date
01-07-2004
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 7/2004
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0631-4

Other articles of this Issue 7/2004

Supportive Care in Cancer 7/2004 Go to the issue

Review Article

Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients

Society News

July 2004

Original Article

Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies

Original Article

“Do not tell”: what factors affect relatives’ attitudes to honest disclosure of diagnosis to cancer patients?

Original Article

Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy

Original Article

High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits